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Sumnlary 
The CD45 transmembrane glycoprotein has been shown to be a protein phosphotyrosine phos- 
phatase and to be important in signal transduction in T and B lymphocytes. We have employed 
gene targeting to create a strain of transgenic mice that completely lacks  expression of all iso- 
forms of CD45. The spleens from CD45-null mice contain approximately twice the number of 
B cells and one fifth the number ofT cells found in normal controls. The increase in B cell num- 
bers is due to the specific expansion of two B cell subpopulations that express high levels ofim- 
munoglobulin (IgM) staining. T  cell development is significantly inhibited in CD45-null ani- 
mals at two distinct stages. The efficiency of the development of CD4-CD8- thymocytes into 
CD4+CD8 § thymocytes is reduced by about twofold, subsequently the frequency of successful 
maturation  of the  double positive population into mature,  single positive thymocytes is  re- 
duced by a further four- to fivefold. In addition, we demonstrate that CD45-null thymocytes 
are severely impaired in their apoptotic response to cross-linking signals  via T  cell receptor 
(TCtk) in fetal thymic organ culture. In contrast, apoptosis can be induced normally in CD45- 
null thymocytes by non-TC1L-mediated signals. Since both positive and negative selection re- 
quire signals through the TCR complex, these findings suggest that CD45 is an important reg- 
ulator of signal  transduction via the TCIk complex at multiple stages of T  cell development. 
CD45 is absolutely required for the transmission ofmitogenic signals via IgM and IgD. By con- 
trast,  CD45-null B  cells proliferate as well as wild-type cells to CD40-mediated signals.  The 
proliferation of B cells in response to CD38 cross-linking is significantly reduced but not abol- 
ished by the CD45-null mutation. We conclude that CD45 is not required at any stage during 
the generation of mature peripheral B cells, however its loss reveals a previously unrecognized 
role for CD45 in the regulation of certain subpopulations of B cells. 
C 
D45 is a transmembrane glycoprotein of variable mo- 
lecular weight (180--220  kD) that is expressed exclu- 
sively by cells of the hemopoietic lineage (for a review see 
reference 1). Alternative splicing of the nascent kNA tran- 
script generates several different protein isoforms that possess 
an intrinsic protein phosphotyrosine phosphatase activity in 
their common cytoplasmic domains (1, 2). CD45 is believed 
to play an important role in antigen receptor signaling in T 
and B lymphocytes (2). Mouse and human T cell lines that are 
deficient in CD45 expression are defective in their ability to 
respond  to  signals  via  their  TCI:k--CD3  complex  (2-5). 
CD45-deficient B  cell lines also  fail to make responses to 
surface  Ig--B  cell receptor (BCI~) 1 complex cross-linking 
(6).  Various  groups  have  also  demonstrated  that  TCtk- 
CD3  signaling  can be restored in  CD45-deficient T  cell 
lines  by  transfection  of phosphatase-active  CD45  or  of 
membrane-bound chimeric proteins containing the  intact 
CD45  cytoplasmic domains (7-11), but not by expression 
of an enzymatically inactive CD45 mutant (12). 
1Abbreviations used in this paper: BCR, B cell receptor for antigen; DN, 
double negative; DP, double positive; ES, embryonic  stem; FTOC, fetal 
thymic organ culture; PTK, protein tyrosine  kinase; SP, single positive. 
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points (13). Early thymocytes rearrange their TCR-[3 chain 
genes and, if rearrangement produces a functional TCR-[3 
chain, express a pre-TCR complex in which TCR-~  asso- 
ciates with pToe and CD3 (14). Formation of this pre-TCR 
complex is  required  for further  development  of the  early 
precursors into immature CD4+CD8 + thymocytes (14,  15) 
that subsequently  rearrange  their  TCR-ot  chain genes.  At 
least one further positive signal is required by the immature 
TCR-o~/f3 +  cells  before  they  complete  their  maturation 
and  migrate  to  the  periphery.  This  second positive  signal 
requires an interaction of TCR-0~/~ with setf-MHC com- 
plexed  with  an  appropriate  peptide  (for review see  refer- 
ences  13,  16).  However,  by means  still  obscure,  MHC/ 
peptide  ligands  can  also  generate  a  negative  signal  giving 
rise to death by apoptosis, thus permitting maintenance of  self- 
tolerance (16). The negative signal may be mimicked in fe- 
tal thymic organ culture (FTOC) by CD3 cross-linking (17). 
We  have  employed gene  targeting  to generate  a  trans- 
genic mouse model in order to study the functions of CD45. 
By specifically targeting an  exon  common to all  isoforms 
(exon 9) we have achieved the first complete knockout of 
the CD45 gene. This new line oftransgenic mice is hereaf- 
ter referred  to as  CD45-null mice.  We have analyzed the 
phenotype  of B  cells  from CD45-null  mice  and  provide 
evidence for a possible role for CD45 in the regulation  of 
peripheral  B  cell  maturation.  We  report  that  CD45  is  an 
important positive regulator of the signals mediated via the 
pre-TCR and TCR  complexes that lead to maturation  or 
to apoptosis.  Consequently, T  cell development is severely 
impaired in CD45-null transgenic mice. Apoptosis as a re- 
sult  of CD3  cross-linking in  FTOC  is  almost  completely 
blocked, whereas the apoptotic pathway triggered by calcium 
ionophore, glucocorticoid, or via the Fas antigen is normal. 
We have  used this  model to study the  requirement  for 
CD45 in B cell activation both via the antigen receptor and 
through  other  pathways  known  to  trigger  tyrosine  phos- 
phorylation.  In human B  cell  lines,  triggering of CD40 by 
mAbs or CD40L induces tyrosine phosphorylation of a num- 
ber of substrates  including protein  tyrosine kinases  (PTKs) 
Lyn, Fyn, and Syk, phospholipase C~/2, and phosphatidyli- 
nositol-3-kinase  (18,  19).  The Lyn kinase  has been impli- 
cated in this process (18). A role for CD45 in the regulation 
of CD40 signaling has been suggested by the effects ofanti- 
CD45 mAbs on CD40-mediated proliferation (19-21). Mu- 
rine  CD38  is  a  transmembrane  type  II glycoprotein with 
ADP-ribosyl cyclase activity and is expressed on resting and 
activated B  cells  (22, 23).  Triggering of CD38 with mAbs 
results in an influx of calcium from the extracellular milieu 
and an increase in tyrosine phosphorylation (24); it also in- 
duces  proliferation  of small  resting  B  cells  and  LPS-acti- 
vated B  cell blasts  (22).  We report that CD45 is differentially 
required for signaling through the BCR, CD40, and CD38. 
Materials and Methods 
Generation of Transgenic Mice.  Gene targeting was achieved using 
a replacement-type targeting vector containing an 8.0-kb BamHI- 
EcoRI fragment of isogenic genomic DNA encompassing exons 
5--9 of  CD45. The pMC1NeopA cassette, corrected for a small point 
mutation thought to reduce the transformation efficiency  of em- 
bryonic stem (ES) cells (25), was inserted  into a BsmI site in exon 
9 in inverse transcriptional  orientation to the CD45 gene. Trans- 
fections were performed with passage 13 of  the (129/Sv  ￿  129/Sv- 
CP)F1  ES line R1  (kindly provided by A. Nagy and J.  Rossant, 
Samuel  Lunenfeld  Research  Institute,  Mount  Sinai  Hospital, 
Toronto,  Canada).  In a typical experiment,  107 cells in 250 p,l 
Hepes buffered saline were transfected  with 40-80 g,g/ml linear- 
ized construct at 0.4 kV, 25 ~F.  Targeted clones were screened 
by Southern blotting using a probe extemal to the targeting con- 
struct.  The targeting frequency was in the range of 1/32-1/188 
G418  R cells. A single clone (5-89) was used to generate,  by blas- 
tocyst injection, 10 fertile male chimeras,  5 of which gave germ- 
line  transmission.  Genotyping was by Southern blotting of tail 
DNA.  Homozygous mutant  animals  were  generated  by inter- 
crossing (R1 ￿  C57BL/6)F  1 CD45 +/- heterozygotes or by inter- 
crossing (R1  ￿  B6) mice backcrossed  to B6 for four generations 
(BC4  ￿  BC4).  The  CD45 genotype of all  individuals  used  in 
these experiments was determined by Southern blotting. Animals 
were maintained in a barrier unit.  Unless otherwise stated, exper- 
iments were performed on 5-9-wk-old animals.  Timed matings 
were performed by pairing a CD45 -/- or +/- male with one to 
two CD45 +/- females overnight. The day of plug was considered 
day 0. 
Cell Preparation.  Thymuses were obtained by dissection  from 
5-8-wk-old mice or fetuses.  Spleens  were  obtained from 5-9- 
wk-old mice. In both cases, tissues were disaggregated  by minc- 
ing with fine forceps and forced through a fine mesh filter to gen- 
erate a single cell suspension.  Total cell numbers were determined 
by microscopic observation using a Neubauer hemocytometer. 
Western Blotting.  Single  cell suspensions  were prepared from 
pooled thymuses from homozygous mutant or wild-type mice. 
Cells were lysed at 2  ￿  108 cells/ml in 10 mM Tris,  pH 7.3,  1 
mM  MgC12, 0.5%  NP-40,  0.02%  sodium  azide,  and  0.1  mM 
PMSF.  Aliquots of each lysate  were  electrophoresed through a 
nonreducing 7% SDS-PAGE gel and electroblotted onto PVDF 
membranes  (ImmobilonTM-P;  Millipore  Corp.,  Bedford,  MA). 
Membranes were blocked for 2 h at 37~  in TSW buffer (10 mM 
Tris,  pH 7.4,  0.1 M  NaCI, 0.1% Triton X-100, and 0.2% SDS) 
containing 3% BSA. Primary antibodies  were an anti-CD45 cyto- 
plasmic domain rabbit antiserum (kindly provided by M.L. Tho- 
mas;  Washington  University,  St.  Louis,  MO)  and  heat-inacti- 
vated normal rabbit serum as a negative control, both at 1/1,000 
in TSW containing 3% BSA and 0.1% sodium azide.  Incubation 
was performed for 16 h at 4~  with gentle shaking,  followed by 
five 30-rain washes in TSW, supplemented with 0.5 M NaC1 and 
1% BSA for the second and fifth washes, respectively.  Secondary 
antibody was  peroxidase-conjugated goat anti-rabbit  Ig (Sigma 
Chemical Co., St. Louis, MO) at a 1/1,000 dilution in TSW 3% 
BSA.  Incubation was  performed  at  room temperature  for 2  h 
with gende shaking,  followed by four 15-min washes  in TSW. 
Specific binding was visualized using enhanced chemiluminescent 
detection reagents for Western blotting (ECL; Amersham Interna- 
tional, Amersham, Bucks., UK). 
Flow Cytometry.  The following reagents and mAbs were used: 
145-2C 11 (hamster IgG, anti-CD3e) was obtained as purified IgG 
(Cedarlane  Laboratories,  Ltd., Hornby, ON) or directly biotiny- 
lated (PharMingen, San Diego, CA); YTS 191.1 (rat IgG2b; anti- 
CD4) was obtained as a PE conjugate (Caltag Laboratories,  South 
San  Francisco,  CA); FITC-conjugated YTS  105.18  (rat  IgG2a, 
anti-CD8),  biotinylated YTS  105.18,  biotinylated YTA3.1  (rat 
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kind gifts from S.P.  Cobbold,  Oxford University,  Oxford,  UK 
(26, 27).  FITC-conjugated 3C7 (rat IgG2b, anti-CD25) was pur- 
chased  from  Sigma  Cheinical  Co.;  PE-conjugated  IM7.8  (rat 
IgG2b, anti-CD44), Jo2  (hamster IgG, anti-Fas), and PE-conju- 
gated  R8-140  (rat  IgG1,  anti  IgL  K)  were  purchased  from 
PharMingen. b7.6 (rat IgG1, anti-IgM) and 1.19 (rat IgG2a, anti- 
IgD) were kindly provided by R.M.E. Parkhouse (Institute  of An- 
imal Health, Pirbright, UK). Single cell suspensions ofthymocytes 
or splenocytes were stained sequentially with appropriate combi- 
nations of these reagents in the presence of 2.5% (vol/vol) heat- 
inactivated normal rabbit serum. Unconjugated antibodies were 
detected by incubation  with an appropriate isotype-specific sec- 
ondary reagent: biotinylated MARG1 (for IgG1) or FITC-conju- 
gated MARG2a (for IgG2a), both from Serotec Ltd., Kidlington, 
OX, UK. Biotinylated antibodies were stained with either FITC- 
Extravidin  TM  (Sigma  Chemical  Co.)  or with  PE-streptavidin  or 
TricolorXM-streptavidin  (both from Caltag Laboratories). Samples 
were fixed after staining with  1% formaldehyde and analyzed by 
FACS  |  (Becton Dickinson & Co., Mountain View, CA) using a 
wide  gate  incorporating  large  and  small  lymphocytes.  20,000 
events per sample were collected in list mode, and analyzed using 
Lysys II software. 
FTOC.  Thymus  lobes  from  14-d  gestation  embryos were 
grown  in  organ  culture  according  to Jenkinson  and  Anderson 
(28).  Pairs  of thymus lobes from individual  embryos were  cul- 
tured separately. To identify the phenotype of each mouse/thy- 
mus,  crude liver cell  preparations from each embryo were  ana- 
lyzed by FACS |  for surface CD45 expression, and the genotype 
was routinely confirmed by Southern blotting of DNA from em- 
bryonic  tissue.  After 7  d  in  FTOC,  thymocytes were  released 
from the thymus by gentle chopping with fine knives. Quantita- 
tion of subpopulations was performed using FACS |  as described 
above. As thymocytes from CD45 +/+  and CD45 +/- mice were 
always equivalent, these were pooled (referred to as CD45+), and 
direcdy compared with CD45-nnll (CD45 -/-) littermates. 
Measurement of Apoptosis.  Total DNA was prepared from 106 
thymocytes immediately after release from the thymus, as in Smith 
et al. (17), and subjected to agarose gel electrophoresis. 
Proliferation Assays.  Splenocytes  were  incubated  at  105  cells 
per well in R-PMI supplemented with 5% FCS.  Mitogens were 
added as follows: PMA  (a gift of D. Wraith,  Bristol University, 
Bristol,  UK) at 50 ng/ml and ionomycin (Molecular Probes, Inc., 
Eugene, OR.) at 400 ng/ml; LPS (Escherichia coli--derived, a gift of 
D. Wraith) at 3 p,g/ml; F(ab')2 fragments of goat anti-mouse lgM 
(Jackson  ImmunoResearch Laboratories, Inc., West Grove, PA) 
at 2-10  p~g/rnl; anti-CD40  (3/23,  Serotec)  at  1-10  p~g/rnl and 
anti-CD38  (NIM-R5, endotoxin-low ascites preparation, a gif~ of 
R.M.E.  Parldaouse) at a 1/500--l/2,000  dilution.  In the anti-IgD 
proliferation  assay, splenocytes were  incubated  at 2 ￿  105  cells 
per well in  RPMI  supplemented  with  10%  FCS  and  anti-IgD 
(purified 1.19, a gift oflL.M.E. Parkhouse) was added at 1.25-10 
~g/ml. Controls consisted of medium plus serum only. All con- 
ditious were prepared in triplicate and incubated at 37~  in 5% 
CO2.  Unless  otherwise  stated,  cultures  were  pulsed  after  72 h 
with 3H[TdR.]  at 1 IxCi/well for 6 h. Results are expressed as the 
mean of each triplicate. 
Results 
The Targeted Mutation in Exon 9 of the CD45 Gene Produces 
a CD45onull Phenotype in Homozygous Mutant Animals.  The 
technique  ofgene targeting by homologous recombination 
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(29) was employed to insert the MCINeopA  cassette in in- 
verse transcriptional  orientation  into  a  unique  site in exon 
9 of the CD45 gene in ES cells. This mutation introduces a 
number of stop codons into the CD45 reading frame down- 
stream  of the  insertion  point.  A  single  targeted  ES  cell 
clone  was  used  to  generate  chimeric  animals  which  gave 
germline  transmission  of the mutated  allele.  The complete 
lack of expression of CD45  in homozygous mutant animals 
was determined  in several ways.  FACS |  analysis of several 
different  lymphoid  compartments  was  performed  using  a 
panel of antibodies specific for CD45 and its isoforms, an ex- 
ample of the results obtained is shown in Fig.  1 A.  CD45- 
null splenocytes stained with the pan-CD45 mAb YBM42.2 
are  indistinguishable  from  cells  stained  with  an  isotype- 
matched  negative  control  (Fig.  1  A).  No  expression  of 
CD45  was  seen  with  seven  other  CD45  mAbs  on  thy- 
mocytes, splenocytes, lymph node or bone marrow cells (data 
not shown).  Confirmation  of these results was achieved by 
immunoprecipitation  (data not shown) and by Western blot-- 
ting  of thymus  lysates  using  both  a  pan-CD45  antibody 
(data not shown) and an antiserum specific for the cytoplas- 
mic domain of CD45  (Fig.  1 B). 
CD45 Is Not Required for the Development of B  Lympho- 
cytes.  The percentage and numbers of mature lymphocytes 
found within the peripheral lymphoid tissue of CD45-null 
mice  were  determined  by enumerating  the  total  numbers 
of cells recovered from the spleens of homozygous mutant 
CD45-null  transgenic  mice  and  by analyzing  cells  stained 
for flow cytometry with a variety of T  and B  cell markers. 
In  all  cases,  wild-type  littermates  were  used  as  controls. 
The total numbers of lymphoid cells residing in the spleen 
of CD45-null  mice  (mean  178  --+  54  ￿  106,  n  =  6)  was 
consistently significantly greater than for wild-type control 
mice  (mean  89  --+  17  ￿  106,  r/  =  6).  However,  despite 
some intersample variation, the percentage of B  cells in the 
CD45-null  mice fell within  the  normal range.  As a  result, 
CD45-null  mice had  approximately twice as many splenic 
B  cells (108  -  12  ￿  106,  n  =  6) as wild-type control mice 
(49  -  12  X  106,  n  =  6). These results indicate that the de- 
velopment  of mature  B  cells  does  not  require  CD45  ex- 
pression. 
CD45-null Mice Have Increased Numbers of Splenic B  Cells 
Expressing High Levels oflgM.  Analysis of surface Ig expres- 
sion  on  CD45-null  B  cells  revealed  an  altered  profile  of 
IgM  and  IgD  staining.  In wild-type  mice,  splenic  B  cells 
can  be  divided  into  three  subpopulations  on  the  basis  of 
IgM versus IgD staining  (30).  Population  I  (IgM low,  IgD 
intermediate-high)  includes  the  predominant  recirculating 
resting B  cell population in spleen and lymph node.  Popu- 
lation  III (IgM high,  IgD low)  includes  newly formed im- 
mature B  cells and B-1  B  cells and is not present in lymph 
nodes of normal mice (30, 31). A  third population  (II) ex- 
presses  both  IgM  and  IgD  at  high  levels.  In  CD45-null 
mice,  a  large increase  in  the  percentage  of splenic  B  cells 
present  in populations  II and  III is seen,  whereas popula- 
tion  I  constitutes  the smallest population  of splenic B  cells 
(Fig. 2). When total splenic cellularity is considered,  popu- 
lation  I  is present  at normal  levels  indicating  that  the  in- Figure 1.  No expression of CD45  on lymphocytes from CD45-null  transgenic mice. (A) Splenocytes were stained with the pan-CD45  antibody 
YBM42.2 (top) or an isotype-matched negative control YTH76.9 (bottom),  detected with FITC-conjugated MARG2a and analyzed by flow cytometry. 
(B) Thymus lysates  were prepared from CD45-null and wild-type mice and the equivalent of  4 ￿  106 cells per lane electrophoresed through a nonreduc- 
ing SDS-PAGE gel and Western blotted. Duplicate samples  were probed with anti-CD45 cytoplasmic  domain antiserum (o~CD45cyt, left) or heat-inacti- 
vated normal rabbit serum as a negative control (NRS, right). 
creased splenic cellularity in CD45-null  mice is partly due 
to  a  large increase in  the  total number  of cells present in 
populations II and III (Table  1)  and also to  an increase in 
the total number of non-B, non-T cells (data not shown). 
To  investigate  further  the  phenotype  of CD45-null  B 
cells, the expression profiles of several B  cell surface mark- 
ers  on  resting  splenic  B  cells  were  analyzed  (data  not 
shown).  Moderate increases were found in the mean fluo- 
rescence levels of several cell surface markers including class 
II MHC  (increased by an average of 1.59  +  0.06-fold over 
that  of wild-type cells), CD40  (average  1.75  +--  0.17-fold 
increase),  and  CD19  (average  1.35  +  0.02-fold).  CD45- 
null and wild-type B  cells upregulate both CD40  and class 
II MHC  expression similarly after overnight culture with a 
combination  of anti-CD40  mAb  and  recombinant  IL-4, 
suggesting  that  these  signals  are  not  regulated  by  CD45 
(data  not  shown).  The  mean  fluorescence  level of CD38 
was unchanged. 
CD45-null  Mice  Have  Low  Numbers  of Mature  T  Cells. 
Fig.  3  shows  the  results  of a  flow  cytometric  analysis  of 
splenocytes  from  CD45-null  and  control  httermate  mice 
for simultaneous staining for the CD3/CD4  (top) and CD3/ 
CD8  (bottom) markers.  The  percentage  of CD3+CD4 +  T 
cells is very markedly reduced in CD45-null transgenic an- 
imals versus  their  littermate  controls,  typically by  at  least 
10-fold.  When  assessed  by  setting  a  region  around  the 
CD3+CD8 +  cell population in wild-type animals, the  ap- 
parent percentage of such CD3+CD8 +  cells in the CD45- 
null mutants  is significantly reduced but  to  a  lesser extent 
than for CD4 +  T  cells, typically three- to fourfold. How- 
CD45+/+  CD45-/- 
y, 
IgM 
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Figure  2.  Profiles of  lgM  versus IgD 
staining for CD45-null  and wild-type sple- 
nocytes. Splenocytes  were stained with anti- 
IgM (B7.6, detected with a combination of 
biotinylated  MARGI  and  PE-coupled 
streptavidin) and  anti-IgD  (1.19, detected 
with FITC-conjugated MARG2a) and ana- 
lyzed by two-color  flow cytometry. Con- 
tour plots were generated for each sample 
showing IgM and IgD fluorescence on the x 
and  y  abscissa, respectively. Square gates 
show  the  distribution  of the  three  major 
populations: I (lgD high-intermediate, lgM 
low), II (IgD high, IgM high), and Ill (IgD 
low, IgM high) and M-D- (DN cells). Both 
plots are representative of many similar pro- 
files. Mice were 5-wk-old. 
Cell Development Table 1.  Percentage  of B Cells in Subpopulations Defined by IgM and IgD 
CD45 +/+ 
Percent B cells  Total B cells (X 10 -6)  Percent B cells 
CD45-/- 
Total B cells (X10 -6) 
Population I  47.66  -+ 7.59*  20.86 +  5.70*  22.14 +  5.14"  21.72  +  4.88  ~; 
Population II  35.63  +  8.35  17.32  -+ 3.21  44.95  +- 7.63  47.22 +- 7.65 
Population III  16.71  +  4.81  8.50 -+ 3.66  32.91  +  11.00  29.40 -+ 12.74 
*Splenocytes were stained with anti-lgM (]37.6) and anti-lgD (1.19) and analyzed by FACS  |  The percentage of splenic B cells in each population 
(corresponding to the regions in Fig. 2) is shown. 
*The total number of B cells in each population was calculated from the percentage of splenocytes in each population  (using regions indicated in 
Fig. 2) and hemocytometer measurements of total lymphocytes. Mice were 5-10-wk-old. Data are expressed as an arithmetic mean +- SD. A mini- 
mum of six mice were included in each group. 
ever careful inspection of the FACS  |  plots suggests the per- 
centage  of CD8 +  T  cells  may  be  overestimated  in  the 
CD45-null  animals since most  of the  gated cells are  only 
weakly stained for CD3 and CD8 and do not form a clearly 
distinct population as in the wild-type controls. 
When  the  increased  splenic  cellularity of homozygous 
mutant animals is taken into account,  the total numbers of 
T  cells present in the spleen of CD45-null transgenic ani- 
mals is ~20% of that of wild-type (6 +  3  ￿  10  6,  n  =  4 for 
mutants compared with 27  +  6  X  106,  n  =  4 in wild-type 
animals). 
Thymocyte  Development  Is Impaired at  Two Distinct  Points. 
To  understand  the  basis for  the  reduced  numbers  of pe- 
CD45+/+  CD45-/- 
o   !i:!ii 
i 
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Figure 3.  The frequency of splenic  T cells is greatly reduced in CD45- 
null mice The percentages ofCD4  + and CD8 + T  cells in the spleen of a 
CD45-nuU homozygous mutant mouse are compared with a control wild- 
type littermate. Splenocytes from 5-wk-old mice were stained with PE- 
CD4,  FITC-CD8,  and  biotin-CD3  (+TricolorT~a-streptavidin) and 
20,000 lymphocytes analyzed by FACScan  |  (Becton Dickinson & Co.). 
The percentages of total lymphocytes in the indicated region are shown 
in each panel. The fluorescence levels are displayed  on a four-decade log- 
arithmic scale. 
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ripheral T  cells in CD45-null transgenic mice, we have in- 
vestigated the development of T  cell precursors in the thy- 
mus.  At a  gross level,  there is an  "~50%  reduction  in  the 
total numbers  of thymocytes recovered from  null mutant 
animals (97  +  30  ￿  106, n  =  5) versus their wild-type con- 
trol littermates (199  +  40  X  106,  n  =  4).  No  differences 
were  seen  in  the  numbers  of thymocytes recovered from 
heterozygous animals (191  +  46  ￿  106,  n  --- 4)  compared 
with wild-type controls. 
The phenotype of the thymocytes recovered from CD45- 
null animals was clearly different from control mice in two 
ways.  Fig.  4  A  shows  the  results of an  analysis for CD4/ 
CD8 expression. CD45-null animals have a distinctly lower 
percentage  of CD4 +  CD8-  single  positive  (SP),  mature 
thymocytes  (2.8  versus  16.7%,  Fig.  4  A).  In addition, the 
mutant  animals  have  an  elevated  percentage  (32  versus 
10%,  Fig. 4 A) of CD4-CD8-  double negative (DN) pre- 
cursors. The percentage of mature CD8 + SP cells is also re- 
duced in mutant animals. In Fig. 4 A  this is obscured by the 
presence of an increased number of CD41~ CD8 + interme- 
diate thymocytes, but on close inspection it is clear that the 
CD4-CD8 + SP population is greatly reduced; this can also 
be elucidated by gating for CD3 ~ cells (data not shown). In 
addition, the level of both CD4 and CD8 expressed by the 
immature  CD4+CD8 +  double  positive  (DP)  cells  is  ele- 
vated in CD45-null mutants versus controls. 
To further investigate the DN precursors present in mu- 
tant  animals, we  analyzed cells stained simultaneously for 
CD4+CD8+CD3  (single  color)  and  independently  for 
CD25  and for CD44.  When the CD25  and CD44 expres- 
sion of the DN  precursors (or triple negative in this case) 
was  examined,  only the  subset  of cells with  the  CD25 + 
CD44-  phenotype  was  found  to  be  present  at  increased 
frequency  (Fig.  4  /3).  Concomitantly,  the  percentage  of 
CD25-  CD44-cells was reduced (Fig. 4 B). 
The actual numbers  of thymocytes at different stages of 
development that were  recovered from  CD45-null  trans- 
genic animals and control httermates are shown in Table 2. 
These data clearly indicate that the number,  as well as the 
percentage, of DN precursors is higher in CD45-null trans- 
genic mice. In addition, the absolute number ofintermedi- CD45+/+  CD45-/- 
CD8 
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Figure  4.  Thymic  development  is inhibited  at both early and late selec- 
tion checkpoints. Thymocytes from a 5-wk-old CD45-null mutant and a 
wild-type control httermate were stained as below and 50,000 cells ana- 
lyzed by FACScan  |  The percentages of the relevant gated cells in the re- 
gions marked on each panel are shown. (A) Cells were stained with PE- 
CD4 and FITC-CD8. (B) Cells were stained with a cocktail containing 
biotinylated antibodies to CD4, CD8, and CD3 and simultaneously  with 
FITC-CD25 and PE-CD44.  A gate was set to  collect data for CD4, 
CD8, CD3 triple negative cells. The profile of CD25 versus CD44 stain- 
ing is shown. 
ate  DP  cells is reduced by more  than  twofold.  Thus,  ab- 
sence of CD45  inhibits the development of DN  cells into 
DP cells. This is most clearly indicated by the ratio of DN/ 
DP  cells in the mice.  CD45-null  transgenic mice have  an 
average DN/DP  ratio of 1:2.0, whereas their wild-type lit- 
termates have  a  ratio of 1:7.7.  The  absence of CD45  also 
inhibits the development of DP cells into mature SP  cells. 
In absolute numbers,  CD45-null  mice have  ~10%  of the 
CD4 §  SP cells found in wild-type mice (Table 2). The ra- 
tio ofDP/CD4  + SP cells is 17.7:1 in CD45-null mice ver- 
sus  4.2:1  in wild-type littermates. These  data demonstrate 
that there is a second point at which CD45 exerts a positive 
effect  on  thymocyte differentiation, namely at  the DP  to 
SP  transition  which  requires  positive selection  by  MHC 
plus peptide (16). 
In  addition  to  the  results  described above,  an  ontoge- 
netic  analysis  of  thymocyte  development  in  CD45-null 
transgenic mice was performed by determining CD4/CD8 
profiles at various stages of development (data not shown). 
The results of this study confirm and expand the results ob- 
tained with adult mice. Before the appearance of DP cells, 
no  differences were  seen  between  mutant  and  wild-type 
thymuses. The first block in development or partial inhibi- 
tion of the differentiation of CD4-CD8-  DN  cells was al- 
ready apparent by day 18 of gestation; the second point of 
inhibition at the DP  to SP transition was apparent on the 
Table 2.  CD4 and CD8 Thymocyte Subsets in CD45-deficient 
Mice 
Total number of positive thymocytes (￿  10-6) 
T  cell subsets  CD45 +/+  CD45 +/-  CD45 -/- 
CD4-CD8-  17.40  +-- 3.85*  13.39  +  2.79  29.17 +  10.36 
CD4+CD8 +  134.03  -+ 29.16  124.95  •  33.59  59.41  +  25.96 
CD4+CD8 -  32.25  +  4.70  35.56 •  6.87  3.35 -  1.02 
CD4-CD8 §  12.12  +  1.70  13.57  +  2.94  2.59  +-- 1.65 
n  4  4  5 
*Thymocytes from  5-wk-old mice were stained with anti-CD4 (PE) 
and anti-CD8 (FlTC) and analysed by FACS  |  Total number of cells in 
each subset were  calculated from  the percentage  of positive  cells in 
two-color dot plots and  hemocytometer measurements  of total  thy- 
mocytes. Data are expressed as an arithmetic mean -+ SD. 
day after birth,  and  the stable adult phenotype was  estab- 
fished by 1 wk after birth (data not shown). These observa- 
tions  reinforce  the  conclusion  that  the  absence  of CD45 
does not affect the development of thymic stem cells or the 
entry ofprothymocytes into the thymic rudiment since no 
differences are apparent at day 16 of gestation. By contrast, 
in the complete absence of CD45 there is a distinct inhibi- 
tion of thymic development both at the DN  to DP and at 
the later DP to SP transitions. 
CD45 Is Required for Negative Selection in FTOC.  The 
FTOC  technique (28) was used to study further the devel- 
opment ofthymocytes from CD45-null mice. As a first step 
we confirmed that the development of CD45-null thymo- 
cytes in FTOC  reproduced the pattern seen in vivo. Thy- 
muses  from  14-d  embryos were  cultured for 7  d  in vitro 
and the number  and phenotype  of the thymocytes recov- 
ered were determined.  The  data demonstrate that  CD45- 
null thymuses contain an elevated percentage of DN  pre- 
cursors and very few cells of CD4 +  SP mature phenotype 
after 7  d  of culture compared with  control thymuses;  this 
can  be  seen  by  comparing  the  ratios  of the  relevant  cell 
populations in unmanipulated cultures shown in Fig. 5  C. 
No  differences  were  noted  between  CD45 +/-  heterozy- 
gotes and  CD45 +/+  homozygotes  (data not  shown).  The 
total yield of thymocytes from CD45-null  (-/-)  thymuses 
was  30-40%  lower  than  from  wild-type or heterozygote 
fittermates (compare untreated control cultures in Fig. 5 B). 
This  is  also  consistent with  the  in  vivo  data.  The  lower 
yield of total thymocytes is essentially accounted for by a 
reduction  in  the  yield  of CD4+CD8 +  DP  thymocytes, 
which in unmanipulated  CD45-null  thymuses  is approxi- 
mately half that from  the  CD45 +  controls (Fig. 5  C,  solid 
bars). In addition, the data in Fig. 5  C  show that more than 
twice the  number  of CD4-CD8-  DN  precursors are re- 
covered from CD45-null thymuses than from their CD45 + 
littermates. 
The  results  of the  analyses of thymocyte  development 
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that  the  CD45-nuU  mutation  significandy  diminishes  the 
eflaciency of positive selection.  Further evidence that posi- 
tive selection is inhibited in CD45-null thymocytes is pro- 
vided  by  an  increase  in  the  basal  level  of apoptosis  in 
CD45-null  FTOC.  Fig.  5  A  shows  the  measurement  of 
apoptosis  by  analysis  of the  integrity  of DNA  obtained 
from FTOC using agarose gel electrophoresis.  A  compari- 
son of the DNA from unmanipulated  thymic lobes shows 
that there is a clear increase in the degree of fragmentation, 
characteristic  of apoptosis,  in  CD45-null  versus  CD45  + 
control cultures (compare control lanes [c] in Fig. 5 A). 
Negative selection of immature DP thymocytes may be 
achieved  in  FTOC  by  delivering  a  strong  signal  via  the 
TCR  complex,  for  example  by  adding  anti-CD3~  mAb 
(17). Treatment of CD45 + FTOC with anti-CD3 induced 
a  significant level  of apoptosis  as  indicated  by DNA frag- 
mentation;  in  contrast,  no increase  over the basal level  of 
apoptosis was observed in similarly treated CD45-nuU thy- 
mocytes  (Fig.  5  A).  Furthermore,  the  yield  of total  thy- 
mocytes from CD45 + thymuses was reduced on average by 
38%  when  anti-CD3  mAb  was  included  in  the  culture, 
whereas  the  yield  of CD45-null  thyrnocytes  was  not  af- 
fected by anti-CD3  treatment  (Fig.  5  B).  Fig.  5  C  shows 
that this  reduction was almost entirely accounted for by a 
loss of CD4+CD8 + DP thymocytes in wild-type thymuses. 
Apoptosis May Be Induced in CD4 5-null Thymocytes by Non- 
TCR Stimuli.  Although the higher basal level ofapoptosis 
Figure  5.  CD3  antibody does not  induce 
apoptosis in CD45-null thymocytes. (A) Total 
DNA from  106  thymocytes from  CD45  + or 
CD45-null thymuses with or without anti-CD3 
mAb (2 p,g/ml) treatment for 15 h was analyzed 
by gel electrophoresis, as labeled. The presence 
of  small molecular  weight DNA fragments indi- 
cates the presence of apoptotic cells. (B)  7-d 
FTOC  were  treated with  anti-CD3  mAb  (2 
Ixg/ml) for 15-20 h (hatched  bars) or cultured in 
medium  alone (solid bars) after which  thy- 
mocytes were released and yields of thymocytes 
determined. The values shown are the means + 
SD  obtained from  five independent  experi- 
ments.  (C)  Thymocyte  subpopulations were 
analysed by FACS  |  after surface staining with 
fluorescent CD4  and CD8  antibodies and the 
numbers of the four subpopulations determined 
with reference to total yields. The data shown 
are from one representative experiment of five 
separate experiments. 
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machinery per se was intact in CD45-null thymocytes, we 
wished  to confirm that stimulation  of apoptosis by signals 
other than via the TCtk complex was intact. Similar FTOC 
experiments  were  performed  in  which  apoptosis  was  in- 
duced  by the  calcium ionophore,  ionomycin,  the  steroid 
dexamethasone,  or via the  Fas  antigen.  The  results  show 
that these three stimuli were equally effective at producing 
apoptosis  in  CD45-null  thymocytes  as  in  CD45 +  thy- 
mocytes (Fig.  6).  All three stimuli  reduced the number of 
viable  thymocytes  recovered  by a  similar  degree  in  both 
CD45-null  and  CD45 +  thymuses  (Fig.  6).  The reduction 
in thymocyte yields is a direct result of apoptotic cell death 
induced by the three treatments.  This was demonstrated by 
measuring  the  percentage  of cells  with  subdiploid  DNA 
content by flow cytometry using 7-amino actinomycin D. 
In each case, the percentage of apoptotic  (subdiploid)  cells 
is similar in CD45 + and CD45-  null thymocytes (data not 
shown).  These  data  demonstrate  that  the  apoptotic  path- 
way is fully functional in CD45-nuU thymocytes. 
CD45 Is Absolutely Required for B Cell Proliferation in Re- 
sponse to Antigen  Receptor Cross-linking and Differentially for 
CD40 and CD38 Responses.  A number of  studies have im- 
plicated CD45 in signaling through the BCR. Proliferation 
assays  were performed in order to analyze the response  of 
the  CD45-null  B  cells  to  a  number  of mitogenic  agents. 
Splenocytes from homozygous mutant  animals  responded 
normally to LPS and at reduced levels to PMA plus iono- 
mycin  when  compared  with  wild-type  cells  (data  not 
shown).  A  mitogenic  preparation  of polyclonal  F(ab')2 
anti-IgM produced a strong proliferative response in wild- 
type  splenic  preparations,  whereas  splenocytes  from  ho- 
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mozygous mutant mice failed to proliferate  in response  to 
anti-IgM at concentrations of ~<20 b~g/ml (Fig. 7 A). Simi- 
larly,  the  CD45-nuU B  cells  were unable  to respond  to a 
mitogenic anti-IgD antibody (Fig. 7 B). These results con- 
firm previous  observations  that  in  CD45-null  B  cells  the 
antigen  receptor  is  uncoupled  from  signaling  pathways 
leading to proliferation and further demonstrate that signal- 
ing through IgD is also CD45 dependent. 
Since the major function of CD45 appears to be the reg- 
ulation of tyrosine phosphorylation in antigen receptor com- 
plexes,  we  considered  whether  it  might  also  regulate  ty- 
rosine  phosphorylation  events  triggered  by other  types of 
receptor.  Several studies  have  described antibodies  against 
CD45 that significantly inhibit anti-CD40-induced prolif- 
eration of human PBL and B  cell lines and murine splenic 
B  cells,  suggesting  a  role  for  CD45  in  the  regulation  of 
CD40  signaling  (19-21).  To  investigate  this  further,  we 
performed proliferation assays to assess the ability of CD45- 
null  B  cells  to  respond  to  a  mitogenic  anti-CD40  mAb 
(32). As shown in Fig. 7  C, splenocytes from homozygous 
mutant mice consistently proliferated as well and frequently 
better than their wild-type counterparts.  This result clearly 
indicates that CD45 is not essential to the CD40 signaling 
pathway. 
We  also  tested  the  requirement  for CD45  in  signaling 
through the CD38 receptor, which has been shown to trig- 
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Figure  6.  Normal induction of apoptosis by non-TCR pathways in 
thymocytes. CD45 + and CD45-null 7-d FTOC were treated with iono- 
mycin (1  laM), dexamethasone (0.01 raM), and anti-Fas mAb (0.5 lag/ 
rot) for 15 h. Total thymocyte yields were determined and the results are 
expressed as a percentage of untreated control cultures in each case. 
Figure  7.  Proliferative  responses of CD45-null splenocytes to stimula- 
tion of the B cell antigen receptor, CD40, and CD38. Splenocytes  were 
incubated in RPMI supplemented with 5% FCS or with the addition of 
anti-lgM as a preparation of polyclonal F(ab')2 fragments of goat anti- 
mouse IgM at 2.5-10.0 lag/ml (A); purified anti-lgD (1.19) at 1.25-10.0 
lag/ml (/3); anti~CD40 (3/23) at 1.0-10.0 lag/ml (C); or anti-CD38 as- 
cites (NIM-R5) at a 1/2,000--1/500 dilution (D). Cultures were pulsed 
after 72 h.  Graphs are plotted from the mean [3H]TdR incorporation 
(cpm) of triplicate cultures of CD45-null splenocytes (0)  or wild-type 
splenocytes (O). 
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ognizes an epitope of CD38 (33); this mAb induced a dose- 
dependent proliferative response in wild-type B  cells (Fig. 
7 D). CD45-null B cells did proliferate in response to anti- 
CD38  but  at  significantly  reduced  levels  compared with 
wild-type  cells  (Fig.  7  D).  This  result  suggests  that,  al- 
though  CD45  is not absolutely required for signalling via 
CD38, it may act to enhance the response through this re- 
ceptor. 
Discussion 
The different isoforms of the CD45 family are encoded 
by multiple mRNA transcripts,  generated by alternative splic- 
ing from a single gene. To achieve a complete knockout of 
the CD45 gene we had to adopt a strategy that would tar- 
get an  exon  common to  all  isoforms.  The  insertion  of a 
neomycin resistance cassette in inverse orientation within 
exon 9 is predicted to affect all transcripts by the introduc- 
tion  of a series of stop  codons  downstream of the  site  of 
disruption.  Cell  surface  expression  of CD45  in  homozy- 
gous mutant animals was undetectable by FACS  |  analysis, 
however the possibility remained that an aberrant sphcing 
event could remove the disrupted exon and the antigenic 
extracellular domain of CD45  while leaving the  cytoplas- 
mic  PTPase  domain  intact.  We  were  unable  to  demon- 
strate the presence  of any form of CD45  in homozygous 
mutant animals by using an antiserum against the cytoplas- 
mic domain of CD45 to probe Western blots of thymus ly- 
sates (Fig.  1 B),  or by immunoprecipitation using the same 
antiserum  (data  not  shown).  We  therefore  conclude  that 
the CD45-null mice described in this study completely lack 
expression of all isoforms of the CD45 gene. This contrasts 
with  a  previous  report  by Kishihara  et  al.  (34)  in  which 
exon 6 of the CD45  gene was deleted by homologous re- 
combination  and  replaced  with  a  neo  expression  cassette. 
The  CD45-exon  6 -/-  mice lack expression of those  iso- 
forms of CD45  that require  exon 6  and,  less  predictably, 
had variable but  reduced  expression  of other isoforms. B 
cells, which in normal mice express the full-length product 
(B220)  as their major isoform, appeared to lack detectable 
surface  CD45  expression  in  the  CD45-exon  6 -/-  mice. 
However some peripheral T  cells  and mature thymocytes 
still  expressed  surface  CD45.  No  analysis  of cytoplasmic 
CD45 domains was reported (34). 
The  frequency of splenic  T  cells is  reduced  in  CD45- 
null mice by a factor of 10 compared with wild-type ani- 
mals, although the absolute number of T  cells per spleen is 
reduced by a factor of only 5 because of a twofold increase 
in the total number ofsplenocytes. We also observed a sim- 
ilarly  significant  reduction  in  T  cell  numbers  in  lymph 
nodes  (data not shown).  The exon 6  mutant mice previ- 
ously described also had a reduced frequency of T  cells in 
the  spleen  and  peripheral lymphoid  organs,  although  the 
reduction (2.5-fold in spleen) was less than we observed in 
CD45-null  mice. However, in contrast to the CD45-null 
transgenic  mice,  no  reduction  in  absolute  numbers  of T 
cells was seen in the spleens of CD45-exon 6-deleted mice 
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since such mice also showed an ~2.5-fold increase in total 
lymphocytes in the spleen compared with wild-type  (34). 
The loss of CD45 appeared to have no adverse effect on B 
cell  development since B  cells were present in CD45-null 
mice in increased numbers.  Kishihara et al.  (34)  reported 
no reduction  in the percentage or absolute numbers of B 
cells  in CD45-exon 6 -/- mice, and although mean num- 
bers or percentages of B  cells were not reported the avail- 
able data on the CD45-exon 6 -/- mice are consistent with 
a  similar expansion of total B  cell numbers.  The  data re- 
ported  here  permit  the  conclusion  that  CD45  is  not  re- 
quired at any stage in B lymphocyte development since we 
are confident that our CD45-null mice do not express any 
CD45  isoforms even in B  cell progenitors or totipotential 
stem cells.  Previously it has been reported that anti-IgM- 
induced  growth inhibition  and DNA fragmentation were 
enhanced in CD45-null mutants of an immature B cell line 
compared with the CD45-positive parental cells  (35).  We 
have not been able to measure directly the rate of loss of B 
cells due to this tolerance mechanism in CD45-null mice. 
However, the increased cellularity within the B  cell com- 
partment of CD45-null mice would argue against a signifi- 
cant  enhancement  of apoptotic  signals  in  the  absence  of 
CD45. To test this conclusion it would be necessary to in- 
troduce  a  rearranged  IgM  transgene  into  the  CD45-null 
background. 
Analysis of the IgM versus IgD expression of CD45-null 
B cells revealed a large increase in the number of cells con- 
tained within populations II (IgM high,  IgD high)  and III 
(IgM  high,  IgD low),  whereas  the  number of B  cells  in 
population I was normal. The relationship between these B 
cell  subpopulations is not certain. Two alternative hypoth- 
eses have been proposed (31, 36). Population I may be de- 
rived from II and III by a peripheral maturation event (36). 
If  so, the altered ratios in CD45-null spleen represent a late 
block in B cell maturation. Alternatively, populations I and 
II correspond to separate lineages (31).  In this case our data 
would represent an expansion of a specific B cell lineage in 
CD45-null mice rather than a block in the maturation of B 
cells. The altered B cell phenotype might be a result of the 
lack of peripheral T  cells in CD45-null mice rather than an 
intrinsic effect of the CD45 mutation in B cells.  However, 
the IgM versus IgD profile of athymic (CBA nu/nu)  mice 
does not resemble that of CD45-null mice and in fact such 
animals displayed a two- to threefold reduction in the per- 
centage of splenic B cells within a population (BLA-1-2+), 
roughly  corresponding  to  population  II  (IgM  high,  IgD 
high)  (36),  which suggests that the altered B  cell profile in 
CD45-null mice cannot be solely attributed to a reduction 
in the number of peripheral T  cells. 
Our studies suggest that the reduced number of mature 
T  cells  in  the  spleen  and  peripheral  lymphoid  organs  of 
CD45-null  mutant mice can be explained by an ~10-fold 
reduction  in the number of mature thymocytes produced 
during thymic development. Several lines of evidence point 
to an influence of CD45 at two distinct checkpoints in thy- 
mic  development.  The  earliest  effect  of the  CD45-null 
phenotype is an inhibition of the transition of CD4-CD8- DN  cells into the CD4+CD8 + DP compartment. This is 
seen in three ways.  Firstly the  "steady-state" yield of DP 
cells from CD45-null  thymuses is approximately half that 
of normal thymuses. Second, the production of DP cells is 
delayed  during  fetal  thymic  ontogeny  (data  not  shown). 
Third, in FTOC, where only a single cohort of developing 
thymocytes is present, the yield of DP cells from CD45-null 
mutant lobes is half that of normal thymic lobes (Fig. 5 B). 
These data consistently show that the absence of CD45 
reduces the number of DP cells by half. This reduction can 
be explained either by a  reduction in the  efficiency with 
which cells pass through the developmental checkpoint, or 
alternatively, by a reduced ability of successful  cells to pro- 
liferate, since this transition is known to be accompanied 
by several rounds of cell division (37).  The evidence sug- 
gests  that the former explanation accounts for most if not 
all of this early developmental effect. Both in steady-state 
and kinetic (ontogenetic and FTOC) studies,  the percent- 
ages and real numbers of DN precursor cells are increased. 
When the DN compartment is further divided by analyz- 
ing DN cells for CD25 and CD44 expression, it is evident 
that  the  partial  block causes  an  accumulation  of CD25 + 
CD44-  DN cells.  Inhibition at this stage  of differentiation 
is also seen in other transgenic mice mutated for TCR-[3, 
pTa, CD3 components or the Lck tyrosine kinase (14,  15). 
These mutants, and other data,  support the hypothesis that 
selection for successful rearrangement of TCR-I3 and forma- 
tion  of the  pre-TCR,  complex  takes  place  at  this  same 
developmental checkpoint (14).  Although it has yet to be 
formally demonstrated that a signal via the pre-TCR is es- 
sential for the DN to DP transition, a role for CD45 in reg- 
ulating this transition is consistent with this hypothesis. 
The second point at which CD45 exerts a positive influ- 
ence on thymic development is the maturation of imma- 
ture DP thymocytes into mature SP cells. The dependence 
on CD45 expression of this second selection step required 
for maturation is greater than at the early checkpoint. The 
numbers and percentages of mature SP cells, developed ei- 
ther in vitro or in vivo, and the ratio of DP/SP cells dem- 
onstrate that the maturation of DP to SP cells is inhibited 
by about fivefold as compared with wild-type cells.  In ad- 
dition,  the  increased basal  level of apoptosis  observed in 
untreated  CD45-null  thymic lobes  is  consistent with  the 
inhibition of positive selection since DP cells that fail to be 
positively (or negatively) selected die  after about  3  d  by 
apoptosis (38). 
The exon 6  mutant mice described by Kishihara et al. 
(34) also showed an inhibition of thymocyte development, 
although in that case the early inhibition was less marked. 
This  report significantly extends  those  observations  since 
the partial nature of the inhibition seen in exon 6 mutant 
mice  could have been  explained by the  residual level of 
CD45  expression,  albeit  much  reduced.  This  study now 
demonstrates conclusively that CD45 is not absolutely re- 
quired for thymocyte development, although it is clearly an 
important regulator of thymocyte maturation.  Previous in 
vitro data are consistent with the hypothesis that the influ- 
ence of CD45  on thymocyte development is  exerted di- 
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rectly on developing thymocytes via involvement in TCR.- 
coupled signal  transduction (for a review see reference 2). 
One caveat, however, which should be borne in mind, is 
that CD45  is also  expressed by thymic dendritic cells and 
macrophages and that FTOC experiments have shown that 
dendritic cells are essential for thymocyte development (39, 
40).  Neither  the  present  nor previous  experiments  have 
formally excluded the possibility that the CD45  might be 
required by accessory cells  for effective interactions with 
developing T  cells  critical  in  selective  events.  Although 
there are no data to support this possibility at present, cell 
transfer experiments, preferably in vivo as well as in organ 
culture, would be required to exclude this hypothesis. 
Our data clearly show that CD45 is important in TCR 
complex-transduced signals leading to apoptosis in FTOC 
and  are  suggestive  that  CD45  regulates  TCR-transduced 
signals  in general. These data apparently conflict with the 
results ofKishihara et al. (34) who found that CD45 exon 6 
mutant mice deleted their TCR VI36  + and TCR V138.1  + 
thymocytes in Mls-1 ~,  H-2  a mice. This apparent discrep- 
ancy may be explained by a low level of CD45 expression 
in  the  exon 6-deleted mice.  Alternatively, the  difference 
between the  in vivo and in vitro systems,  perhaps in the 
strength of the TCR signals  or the combination of TCR. 
signals  with accessory signals,  may account for the  appar- 
ently contradictory results.  A clearer resolution of this issue 
could  be  provided  by  crossing  the  CD45-null  mutation 
onto a TCR  transgenic background.  We  note,  however, 
that the avidity-affinity model ofthymocyte selection would 
predict  that  early  acting  regulators  of positive  selection 
would also affect negative selection (16).  Indeed, our data 
showing a more profound inhibition of negative than posi- 
tive selection, is entirely consistent with the affinity-avidity 
model if, as we propose, CD45 acts as a positive regulator 
of TCR complex signaling. 
Evidence from in vitro B cell lines and from in vivo-tar- 
geted mutagenesis demonstrates that CD45  is required for 
signal transduction after cross-hnking ofslgM (6, 34). Con- 
sistent with these previous studies, splenocytes from CD45- 
null mice were completely unable to prohferate in response 
to anti-IgM. In addition, we have shown that CD45 is also 
absolutely required for slgD  signaling.  The latter result is 
not surprising since despite the ability of slgD and slgM to 
trigger different physiological outcomes and some evidence 
for  IgD-receptor-specific  associated  proteins  (41),  only 
subtle temporal differences have been observed in their sig- 
nal transduction pathways (42). 
Our finding that CD45-null B cells were not impaired in 
their  ability  to  respond  to  a  mitogenic  anti-CD40  mAb 
contrasts with previous reports in which anti-CD45 mAbs 
inhibited CD40-mediated B cell proliferation (19-21). An- 
tibody inhibition studies of this kind require careful inter- 
pretation and may be explained in terms of stochiometric 
mechanisms such as sequestration of CD45 or inappropriate 
interaction of CD45 with substrates  (43).  It remains possi- 
ble that, under certain circumstances, CD45 may influence 
some aspect of the CD40 signaling pathway, but the physi- 
ological relevance of this interaction is unknown. 
Cell Development and Late B Cell Development CD38 is a receptor that triggers tyrosine phosphorylation 
events but does not possess intrinsic PTK activity (24). The 
identity of the PTK(s) activated by CD38 is at present un- 
known,  however our finding that  CD38-mediated  prolif- 
eration is reduced in CD45-nttll mice suggests that at least 
one of these PTKs is a src family kinase that is activated by 
CD45. Recently it was shown that in physiological states of 
B  cells in which anti-IgM activation is blocked, anti-CD38 
activation is also inhibited  (44).  Lurid et al.  (44)  suggested 
that  the  data indicated  that a  critical  signaling component 
was  common  to  both  pathways.  Our  data  are  consistent 
with an overlap between the pathways but do not identify 
the shared component(s). 
In summary, CD45 acts as a positive regulator of signals 
delivered  via the  TCR  and BCR  complexes,  so  that  the 
signaling threshold of these receptors is markedly increased 
in  the  absence  of CD45.  The  extent  to which functional 
consequences of antigen receptor triggering are inhibited in 
the absence of CD45 varies. Previous studies analyzing the 
defect in TCR  signaling using in vitro T  cell fines that lack 
CD45 expression have suggested that CD45 exerts its effect 
by regulating the phosphorylation state of the COOH-ter- 
minal tyrosine of the lck andfyn kinases 05-47). Analysis of 
the biochemical basis for the signal reduction in CD45-null 
lymphocytes is in progress. 
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